Inspiration Launches Second Trial of OBI-1 in Hemophilia A
By Marie Powers
Monday, November 28, 2011
Inspiration Biopharmaceuticals Inc. initiated patient enrollment in the second of two pivotal studies of the company's OBI-1 Accur8 Phase III hemophilia program.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.